- Home
- USIO vs PASG Comparison
USIO vs PASG Comparison
Compare USIO & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- PASG
- Stock Information
- Founded
- USIO 1998
- PASG 2017
- Country
- USIO United States
- PASG United States
- Employees
- USIO N/A
- PASG N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- PASG Health Care
- Exchange
- USIO Nasdaq
- PASG Nasdaq
- Market Cap
- USIO 36.6M
- PASG 31.1M
- IPO Year
- USIO N/A
- PASG 2020
- Fundamental
- Price
- USIO $1.56
- PASG $0.33
- Analyst Decision
- USIO Strong Buy
- PASG Strong Buy
- Analyst Count
- USIO 2
- PASG 3
- Target Price
- USIO $5.00
- PASG $7.67
- AVG Volume (30 Days)
- USIO 50.2K
- PASG 193.6K
- Earning Date
- USIO 05-14-2025
- PASG 05-20-2025
- Dividend Yield
- USIO N/A
- PASG N/A
- EPS Growth
- USIO N/A
- PASG N/A
- EPS
- USIO 0.12
- PASG N/A
- Revenue
- USIO $82,931,840.00
- PASG N/A
- Revenue This Year
- USIO $16.14
- PASG N/A
- Revenue Next Year
- USIO $13.51
- PASG N/A
- P/E Ratio
- USIO $13.17
- PASG N/A
- Revenue Growth
- USIO N/A
- PASG N/A
- 52 Week Low
- USIO $1.24
- PASG $0.30
- 52 Week High
- USIO $2.92
- PASG $1.64
- Technical
- Relative Strength Index (RSI)
- USIO 51.96
- PASG 43.93
- Support Level
- USIO $1.56
- PASG $0.33
- Resistance Level
- USIO $1.68
- PASG $0.42
- Average True Range (ATR)
- USIO 0.09
- PASG 0.04
- MACD
- USIO -0.01
- PASG 0.00
- Stochastic Oscillator
- USIO 47.83
- PASG 17.88
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.